The U.S. Food and Drug Administration (FDA) has approved SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor developed by AbbVie, for the treatment of adults with moderately to severely active ulcerative colitis. This marks a significant milestone as SKYRIZI becomes the first IL-23 specific inhibitor approved for this condition, in addition to its approval for moderate to […]
In a significant advancement for patients with digestive disorders, Celltrion USA has announced the availability of ZYMFENTRA (infliximab-dyyb), marking it as the first and only subcutaneous formulation of infliximab approved by the U.S. Food and Drug Administration (FDA) in 2023. This revolutionary treatment offers a new hope and convenience for adults suffering from moderately to […]
